Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush

Wedbush restated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB) in a research report released on Tuesday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday. BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an outperform rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a buy rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an underweight rating for the company in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a buy rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $21.14.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $13.24 on Tuesday. Y-mAbs Therapeutics has a 1 year low of $4.69 and a 1 year high of $20.90. The stock’s 50-day simple moving average is $12.62 and its 200-day simple moving average is $13.61. The firm has a market cap of $590.11 million, a price-to-earnings ratio of -27.02 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. As a group, research analysts predict that Y-mAbs Therapeutics will post -0.57 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 21.50% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth approximately $562,000. Squarepoint Ops LLC lifted its position in Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares during the period. Millennium Management LLC boosted its stake in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Boston Partners bought a new stake in shares of Y-mAbs Therapeutics in the 1st quarter worth $556,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.